Herein, we found that HER2-positive breast cancer patients harboring high circ-β-TrCP displayed worse overall survival than those harboring low circ-β-TrCP, indicating that circ-β-TrCP may be a prognostic biomarker for HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.